Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma, Cancer Research, vol.70, issue.4, pp.1408-1418, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3419
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, issue.3, pp.787-794, 2001. ,
DOI : 10.1182/blood.V98.3.787
The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival, Cancer Res, vol.63, pp.8226-8232, 2003. ,
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference, Blood, vol.111, issue.3, pp.1617-1624, 2008. ,
DOI : 10.1182/blood-2007-02-068791
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis, Blood, vol.109, issue.12, pp.5422-5429, 2007. ,
DOI : 10.1182/blood-2006-11-057208
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma, British Journal of Haematology, vol.64, issue.3, pp.303-316, 2006. ,
DOI : 10.1111/j.1365-2141.2005.05883.x
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways, British Journal of Haematology, vol.104, issue.4, pp.516-526, 2005. ,
DOI : 10.1186/1471-213X-2-8
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma, Cancer Cell, vol.3, issue.2, pp.185-197, 2003. ,
DOI : 10.1016/S1535-6108(03)00028-X
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct geneexpression profiles allowing molecular diagnosis, Blood, vol.103, pp.2727-2737, 2004. ,
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, vol.14, issue.7277, pp.88-92, 2010. ,
DOI : 10.1038/nature08638
Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression, Cancer Research, vol.66, issue.14, pp.7158-7166, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0085
Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation, Leukemia, vol.93, issue.9, pp.1984-1991, 2007. ,
DOI : 10.1182/blood-2002-06-1683
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, vol.95, issue.11, pp.1865-1872, 2010. ,
DOI : 10.3324/haematol.2009.019745
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling, Cellular Oncology, vol.4, issue.2, pp.141-153, 2011. ,
DOI : 10.1007/s13402-011-0019-7
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases, Blood, vol.118, issue.11, pp.3088-3095, 2011. ,
DOI : 10.1182/blood-2011-03-343434
The tipping points in the initiation of B cell signalling: how small changes make big differences, Nature Reviews Immunology, vol.174, issue.11, pp.767-777, 2010. ,
DOI : 10.1038/nri2853
Map kinase signaling pathways and hematologic malignancies, Blood, vol.101, issue.>12, pp.4667-4679, 2003. ,
DOI : 10.1182/blood-2002-12-3647
Distinct types of diffuse large B-cell lymphoma identified by gene expression
profiling, Nature, vol.303, issue.6769, pp.503-511, 2000. ,
DOI : 10.1038/35000501
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines, Oncogene, vol.22, issue.54, pp.8797-8801, 2003. ,
DOI : 10.1038/sj.onc.1206919
JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125, The Journal of Pathology, vol.29, issue.1, pp.95-103, 2009. ,
DOI : 10.1002/path.2521
The Role of MAPKs in B Cell Receptor-induced Down-regulation of Egr-1 in Immature B Lymphoma Cells, Journal of Biological Chemistry, vol.281, issue.52, pp.39806-39818, 2006. ,
DOI : 10.1074/jbc.M604671200
Role of Egr-1 Gene Expression in B Cell Receptor-induced Apoptosis in an Immature B Cell Lymphoma, Journal of Biological Chemistry, vol.272, issue.44, pp.27987-27993, 1997. ,
DOI : 10.1074/jbc.272.44.27987
cDNA cloning of mRNAS which increase rapidly in human lymphocytes cultured with concanavalin-A and cycloheximide, Biochemical and Biophysical Research Communications, vol.129, issue.3, pp.619-625, 1985. ,
DOI : 10.1016/0006-291X(85)91936-9
Constitutive and Inducible Levels of egr-1 and c-myc Early Growth Response Gene Expression in Self-Renewing B-1 Lymphocytes, Cellular Immunology, vol.162, issue.2, pp.309-314, 1995. ,
DOI : 10.1006/cimm.1995.1083
Early growth response 1 (EGR1): A gene with as many names as biological functions, Cancer Biology & Therapy, vol.8, issue.20, pp.1889-1892, 2009. ,
DOI : 10.4161/cbt.8.20.9804
c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells, Blood, vol.106, issue.4, pp.1382-1391, 2005. ,
DOI : 10.1182/blood-2004-10-3819
Membrane-associated signaling in human B-lymphoma lines, Experimental Cell Research, vol.317, issue.2, pp.151-162, 2011. ,
DOI : 10.1016/j.yexcr.2010.09.011
Essential function for the kinase TAK1 in innate and adaptive immune responses, Nature Immunology, vol.165, issue.11, pp.1087-1095, 2005. ,
DOI : 10.1093/intimm/dxf046
Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State, Journal of Biological Chemistry, vol.284, issue.1, pp.284-291, 2009. ,
DOI : 10.1074/jbc.M807850200
Early growth response transcription factors and the modulation of immune response, Autoimmunity Reviews, vol.9, issue.6, pp.454-458, 2009. ,
DOI : 10.1016/j.autrev.2009.12.006
Egr-1 expression in surface Ig-mediated B cell activation. Kinetics and association with protein kinase C activation, J Immunol, vol.145, pp.3647-3653, 1990. ,
Early Growth Response Protein 1 (Egr-1): Prototype of a Zinc-finger Family of Transcription Factors, Prog Nucleic Acid Res Mol Biol, vol.50, pp.191-224, 1995. ,
DOI : 10.1016/S0079-6603(08)60815-6
Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes., Molecular and Cellular Biology, vol.16, issue.5, pp.2283-2294, 1996. ,
DOI : 10.1128/MCB.16.5.2283
The role of early growth response gene 1 (egr-1) in regulation of the immune response, J Leukoc Biol, vol.60, pp.159-166, 1996. ,
Essential role of TAK1 in regulating mantle cell lymphoma survival, Blood, vol.120, issue.2, pp.347-355, 2012. ,
DOI : 10.1182/blood-2011-07-369397
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM, Oncogene, vol.24, issue.8, pp.1348-1358, 2005. ,
DOI : 10.1038/sj.onc.1208300
Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells, Blood, vol.109, issue.9, pp.3989-3997, 2007. ,
DOI : 10.1182/blood-2006-09-045377
CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1, International Immunology, vol.11, issue.6 ,
DOI : 10.1093/intimm/11.6.871
Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts, Blood, vol.111, issue.4, pp.2310-2320, 2008. ,
DOI : 10.1182/blood-2007-05-090985
Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma, Molecular & Cellular Proteomics, vol.8, issue.7, pp.1501-1515, 2009. ,
DOI : 10.1074/mcp.M800515-MCP200
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib, Leukemia, vol.177, issue.9, pp.1755-1766, 2008. ,
DOI : 10.1038/sj.onc.1209510
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure, Clinical Cancer Research, vol.12, issue.23, pp.7180-7186, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-1112
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, Clinical Cancer Research, vol.17, issue.9, pp.2977-2986, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2879
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS, Annals of Oncology, vol.23, issue.6, pp.1555-1561, 2012. ,
DOI : 10.1093/annonc/mdr450
URL : https://hal.archives-ouvertes.fr/hal-00744066
Establishment and characterization of a new human lymphoma-derived cell line, p.2 ,